{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:08:33Z","timestamp":1759838913739,"version":"3.37.3"},"reference-count":60,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU2RGH001915-02-00"],"award-info":[{"award-number":["NU2RGH001915-02-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.04.037","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T21:29:30Z","timestamp":1682717370000},"page":"3718-3727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outbreak management strategies for cocirculation of multiple poliovirus types"],"prefix":"10.1016","volume":"41","author":[{"given":"Dominika A.","family":"Kalkowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Badizadegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.037_b0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/jiac130","article-title":"Polio by the numbers-A global perspective","volume":"226","author":"Badizadegan","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/risa.12019","article-title":"Preeradication vaccine policy options for poliovirus infection and disease control","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1539-6924.2012.01864.x","article-title":"Expert review on poliovirus immunity and transmission","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0020","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1093\/infdis\/jit601","article-title":"Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis","volume":"210","author":"Grassly","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2023.04.037_b0030","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Duintjer Tebbens","year":"2006","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.04.037_b0040","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/risa.12022","article-title":"Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0045","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/erv.11.195","article-title":"Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation","volume":"11","author":"Thompson","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.037_b0050","unstructured":"World Health Organization. 14th Meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC), Bali, Indonesia, 20-21 September, 2015 Summary of findings, decisions and recommendations. Available at: http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/1Report.pdf. Accessed Jul 22 2021."},{"key":"10.1016\/j.vaccine.2023.04.037_b0055","first-page":"934","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2023.04.037_b0060","doi-asserted-by":"crossref","unstructured":"Macklin G, Peak C, Eisenhawer M, et al. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine Vaccine 2023 Apr 6;41 Suppl 1:A122-A127. doi: 10.1016\/j.vaccine.2022.02.050. Epub 2022 Mar 17.","DOI":"10.1016\/j.vaccine.2022.02.050"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0065","doi-asserted-by":"crossref","first-page":"A70","DOI":"10.1016\/j.vaccine.2022.02.058","article-title":"Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal","volume":"41","author":"Harutyunyan","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.037_b0070","unstructured":"World Health Organization. Recommendation for an emergency use listing (EUL) of novel oral polio vaccien type 2 (nOPV2 Submitted by PT Biofarma (Persero) Available at: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/nOPV2_EUL_recommendation.pdf. Accessed Jan 24 2023."},{"key":"10.1016\/j.vaccine.2023.04.037_b0075","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000\u20132019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.037_b0080","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1093\/infdis\/jix108","article-title":"Lessons from the polio endgame: Overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/risa.13665","article-title":"An updated economic analysis of the Global Polio Eradication Initiative","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12688\/gatesopenres.13524.1","article-title":"Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative","volume":"6","author":"Thompson","year":"2022","journal-title":"Gates Open Res"},{"key":"10.1016\/j.vaccine.2023.04.037_b0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2334-14-45","article-title":"The potential impact of expanding target age groups for polio immunization campaigns","volume":"14","author":"Duintjer Tebbens","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0100","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1093\/infdis\/jit844","article-title":"Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India","volume":"210","author":"Kalkowska","year":"2014","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0105","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/infdis\/jit834","article-title":"Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria","volume":"210","author":"Kalkowska","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0110","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12879-015-1116-4","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1539-6924.2012.01891.x","article-title":"Modeling population immunity to support efforts to end the transmission of live polioviruses","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infecti Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14760584.2017.1322514","article-title":"Poliovirus vaccination during the endgame: Insights from integrated modeling","volume":"16","author":"Duintjer Tebbens","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.037_b0130","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/infdis\/jiab160","article-title":"Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response options","volume":"224","author":"Kalkowska","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of poliovirus outbreak response strategies for 2019\u20132029: Impacts of the use of novel OPV2 strains","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0140","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1016\/j.vaccine.2021.04.061","article-title":"Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0145","doi-asserted-by":"crossref","first-page":"A142","DOI":"10.1016\/j.vaccine.2022.10.060","article-title":"Outbreak response strategies with type 2-containing oral poliovirus vaccines","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.037_b0150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-020-0176-7","article-title":"Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization","volume":"5","author":"Konopka-Anstadt","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.037_b0155","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/jiab507","article-title":"Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine\/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials","volume":"226","author":"Gast","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0160","doi-asserted-by":"crossref","unstructured":"Kalkowska DA, Badizadegan K, Thompson KM. Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. Risk Anal 2023 Apr;43(4):660-676. doi: 10.1111\/risa.13983. Epub 2022 Jun 23.","DOI":"10.1111\/risa.13983"},{"year":"2022","series-title":"Standard Operating Procedures - Responding to a Poliovirus Event or Outbreak - Version 4","author":"WHO","key":"10.1016\/j.vaccine.2023.04.037_b0165"},{"key":"10.1016\/j.vaccine.2023.04.037_b0170","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/aje\/kwi206","article-title":"A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future","volume":"162","author":"Duintjer Tebbens","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.04.037_b0175","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1539-6924.2006.00843.x","article-title":"Evaluation of response scenarios to potential polio outbreaks using mathematical models","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12879-015-0791-5","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination","volume":"15","author":"Kalkowska","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0185","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0190","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1093\/infdis\/jit838","article-title":"Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation","volume":"210","author":"Duintjer Tebbens","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.037_b0195","first-page":"107","article-title":"Another look at silent circulation of poliovirus in small populations","volume":"3","author":"Kalkowska","year":"2018","journal-title":"Infect Dis Model"},{"key":"10.1016\/j.vaccine.2023.04.037_b0200","unstructured":"World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Part 1: General SOPs. Available at: https:\/\/s3.amazonaws.com\/gpei-tk\/reference_links\/en\/GPEI_SOPs.pdf. Accessed April 20 2016."},{"key":"10.1016\/j.vaccine.2023.04.037_b0205","unstructured":"World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Part 2: Protocol for poliovirus type 2. Available at: http:\/\/polioeradication.org\/wp-content\/uploads\/2018\/01\/pol-sop-responding-polio-event-outbreak-part2-20180117.pdf. Accessed August 20 2020."},{"key":"10.1016\/j.vaccine.2023.04.037_b0210","unstructured":"World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Version 3, January 2019. Available at: http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/sop-polio-outbreak-response-version-20193101.pdf. Accessed August 20 2020."},{"key":"10.1016\/j.vaccine.2023.04.037_b0215","unstructured":"World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Version 3.1, March 2020. Available at: http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/POL-SOP-V3.1-20200424.pdf. Accessed August 20 2020."},{"key":"10.1016\/j.vaccine.2023.04.037_b0220","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/risa.12031","article-title":"Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0225","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/risa.12044","article-title":"Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0230","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/risa.13447","article-title":"Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0235","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.04.037_b0240","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1016\/j.vaccine.2021.04.026","article-title":"The impact of disruptions caused by the COVID-19 pandemic on global polio eradication","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2023.04.037_b0245","doi-asserted-by":"crossref","first-page":"e1807","DOI":"10.1016\/S2214-109X(22)00412-0","article-title":"Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021","volume":"10","author":"Mirzoev","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.04.037_b0250","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/risa.13671","article-title":"No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the editor by Chumakov et al]","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0255","doi-asserted-by":"crossref","first-page":"1098419","DOI":"10.3389\/fpubh.2023.1098419","article-title":"Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation","volume":"11","author":"Thompson","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2023.04.037_b0260","article-title":"Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences","author":"Kalkowska","year":"2023","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0265","unstructured":"Kalkowska DA, Wassilak SGF, Wiesen E, et al. Worst-case scenarios: Modeling uncontrolled type 2 polio transmission. In review."},{"key":"10.1016\/j.vaccine.2023.04.037_b0270","unstructured":"Global Polio Eradication Initiative. Polio Now - This Week. Available at: https:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/. Accessed 19 Jan 2023."},{"key":"10.1016\/j.vaccine.2023.04.037_b0275","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/risa.13557","article-title":"Potential future use, costs, and value of poliovirus vaccines","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2023.04.037_b0280","unstructured":"World Health Organization Global Polio Eradication Initiative. Interim guidance on the use of novel oral polio vaccine type 2 (nOPV2) for the response to type 2 circulating vaccine-derived poliovirus (cVDPV2) during the initial use period (Addendum to the standard operating procedures for response to a poliovirus event or outbreak, version 3.1). Available at: https:\/\/polioeradication.org\/wp-content\/uploads\/2020\/11\/EN-interim-Guidance-on-the-use-of-nOPV2-during-the-initial-use-period-Oct2020.pdf. Accessed Nov 7 2022."},{"key":"10.1016\/j.vaccine.2023.04.037_b0285","first-page":"197","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, 22\u201324 March 2021: conclusions and recommendations","volume":"96","author":"World Health Organization","year":"2021","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2023.04.037_b0290","first-page":"613","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2021: conclusions and recommendations","volume":"96","author":"World Health Organization","year":"2021","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2023.04.037_b0295","unstructured":"World Health Organization Global Polio Eradication Initiative. Novel oral polio vaccine (nOPV2) management, monitoring, removal and disposal (in 50-dose vials with VVM type 2), Technical guidance. Available at: https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/10\/nOPV2-vaccine-handling.pdf. Accessed Nov 7 2022."},{"key":"10.1016\/j.vaccine.2023.04.037_b0300","doi-asserted-by":"crossref","first-page":"e023938","DOI":"10.1136\/bmjopen-2018-023938","article-title":"Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission","volume":"9","author":"Duintjer Tebbens","year":"2019","journal-title":"BMJ Open"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:15:57Z","timestamp":1722428157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":60,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23004292"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outbreak management strategies for cocirculation of multiple poliovirus types","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}